Pune, Oct. 04, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Thrombin Market by Product (Human Thrombin, Bovine Thrombin, Recombinant Thrombin), by Dosage Form (Solution Form, Powder Form), by End-User (Diagnostics Centers & Clinics, Academic and Research Institutes, Hospitals) – Global Outlook & Forecast 2022-2030" published by Growth Plus Reports, the thrombin market is expected to grow at a CAGR of 3.80% from 2021 to reach US$ 797 million by 2030 due to high incidence of thrombosis and inherited blood clotting disorders.

The rising prevalence of thrombin disorders such as hemophilia, and antiphospholipid syndrome is increasing the necessity of novel drugs in the market.  For instance, Sevenfact coagulation factor VIIa, which has been approved by the US Food and Drug Administration in April 2020 for the treatment and management of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with inhibitors, is now approved. Sevenfact is the first hemophilia therapy product with an active ingredient derived from genetically modified rabbits to produce a protein required for blood coagulation is called Sevenfact.

Get the Exclusive Sample PDF of this report now @ https://growthplusreports.com/inquiry/request-sample/thrombin-market/7831

Excerpts from ‘by Product’

The global thrombin market is divided into three product categories:

• Human Thrombin

• Bovine Thrombin

• Recombinant Thrombin

The bovine sourced thrombin has shown highest growth over the years. Due to its reasonable prices, it is the most widely utilized product, and it is projected that the sector would continue to rule the market during the projection period. The industry is also being impacted by the rising usage of products derived from bovines in various diagnostic and research procedures. Additionally, it is advised to use a high concentration of topical bovine thrombin to aid in hemostasis when apparent bleeding from capillaries and small venules cannot be stopped with conventional surgical techniques (such as suture, ligature, or cautery). Due to its widespread use and the potential for contamination in animal-based thrombin, other segments, such as human-based thrombin, are also anticipated to exhibit substantial growth throughout the projected period. Human thrombin also benefits from low antigenicity levels and no risk of viral transmission. Hemostasis is usually achieved by combining thrombin with additional hemostatic agents, such as absorbable compounds like Gelfoam and fibrinogen in fibrin glues.

Excerpts from ‘by Dosage Form’

The global thrombin market is divided into two categories based on dosage type:

• Solution Form

• Powder Form

The solution form thrombin has experienced rapid expansion as a result of the high rate of physician adoption, clinical efficacy, and stability compared to powder form. Due to the widespread endorsement of the Pfizer product THROMBIN-JMI, the powder market is also predicted to expand over the course of the projection period. This thrombin, which has a bovine origin, is produced as a sterile powder that has been freeze-dried. Additionally, compared to solution form, the powder form is far more stable.

Excerpts from ‘By Region’

The North American, European, Asia Pacific, and Rest of the World regions make up the global thrombin market. North America is predicted to dominate the market over the forecast period. The market is expanding due to the existence of major market participants, a high frequency of accidents and property damage in the region, and an increase in the prevalence of inherited blood disorders. The well-established healthcare infrastructure might also be held responsible for a significant portion of market share. Additionally, it is projected that supportive government measures and an increase in research collaborations will accelerate industry expansion. The United States has the highest stake in this region as a result of its pro-patient legislation, sizable patient population, and advanced healthcare market. Due to a high prevalence of blood clotting diseases and pharmaceutical companies' keen interest in therapeutic development, the European market is expanding steadily. Asia Pacific will experience high growth during the forecast period due to early availability of new technologies, high awareness, significant health care spending in overall national budgets, and extensive research activity in these countries.

Inquiry Before Buying: https://growthplusreports.com/inquiry/before-buying/thrombin-market/7831

Excerpts from ‘Competitive Landscape’

Some of the prominent players operating in the global thrombin market are:

• Bayer AG

• Takeda Pharmaceutical Company

• Pfizer Inc

• GE Healthcare Systems

• Johnson and Johnson Services Inc

• Baxter International Inc

• Octapharma AG

• Grifols S.A

• Omrix Biopharmaceuticals, Inc

• Hualan Biological Engineering Inc

Table of Content

1. INTRODUCTION

   1. Market Ecosystem

   2. Timeline Under Consideration

      1. Base Year – 2021

      2. Historical Years – 2020

      3. Forecasted Years – 2022 to 2030

   3. Currency Used in the Report

2. RESEARCH METHODOLOGY 

   1. Research Approach

   2. Data Collection Methodology

   3. Data Sources

      1. Secondary Sources

      2. Primary Sources

   4. Market Estimation Approach

      1. Bottom Up

      2. Top Down

   5. Market Forecasting Model

   6. Limitations and Assumptions       

3. PREMIUM INSIGHTS

   1. Current Market Trends (COVID-19 Perspective)

   2. Key Players & Competitive Positioning

4. MARKET DYNAMICS

   1. Drivers

   2. Restraints

   3. Opportunities

5. GLOBAL THROMBIN MARKET - ANALYSIS & FORECAST, BY PRODUCT  

   1. Human Thrombin

   2. Bovine Thrombin

   3. Recombinant Thrombin

6. GLOBAL THROMBIN MARKET - ANALYSIS & FORECAST, BY DOSAGE FORM

   1. Solution Form

   2. Powder Form

7. GLOBAL THROMBIN MARKET - ANALYSIS & FORECAST, BY END USER 

   1. Diagnostics Centres & Clinics

   2. Academic and Research Institutes

   3. Hospitals

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

• Comprehensive quantitative and qualitative insights at segment and sub-segment level

• Covid 19 impact trends and perspective

• Granular insights at global/regional/country level

• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

• Blanket coverage on competitive landscape

• Winning imperatives

• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment

• Pricing Intelligence

• Customer Base Assessment

• Investment & Initiatives Analysis

• 'Business Profile' of Key Players

Directly Purchase Premium Copy of Thrombin Market Growth Report (2022-2030) at:  https://growthplusreports.com/checkout?_token=4KAVtI3qrNCOyNkleQKUm3PfLxi7ukO70q3lsu2z&report_id=7831&license=Single&submit=

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: enquire@growthplusreports.com Phone no: +91 96545 76783 Web: https://growthplusreports.com/  Follow Us: LinkedIn | Twitter